Clyde Biosciences completes 300th study milestone

Clyde Biosciences, a leading CRO specialising in in vitro human cardiomyocyte safety and heart failure studies, has proudly completed its 300th client study—a major milestone reflecting over a decade of scientific partnership with pharmaceutical companies, biotechs, and regulatory agencies worldwide.

Since its founding, Clyde has delivered high-quality, predictive in vitro cardiac data to support early decision-making in both safety pharmacology and efficacy evaluation across a wide range of therapeutic areas and modalities.

At the core of this success is CellOPTIQ®, Clyde’s proprietary platform enabling simultaneous measurement of voltage, calcium, and contractility in spontaneously beating or paced hiPSC-derived cardiomyocytes. This integrated approach allows early detection of proarrhythmic risk, negative inotropy, and cardiotoxicity, helping clients avoid costly late-stage failures.

Clyde has also played a critical role in regulatory engagement—delivering CiPA-compliant myocyte data to support IND submissions, aligned with the latest ICH S7B/E14 Q&A guidance.

In the heart failure space, Clyde has provided key mechanistic and efficacy data to advance novel therapeutic candidates, supporting translational development and early-stage proof of concept.

With a growing client base and expanding service offering, Clyde continues to establish itself as the partner of choice for in vitro cardiomyocyte studies in drug safety and discovery.